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Background:Despite the absence of a relationship between cholesterol and abdominal aortic aneurysm (AAA) expansion,
there is evidence from a number of studies to suggest that statin therapy may influence AAA expansion, presumably
through pleiotropic effects. To confirm whether statin therapy is associated with less AAA expansion, we performed a
meta-analysis of clinical controlled studies of statin therapy for prevention of AAA expansion.
Methods: To identify all clinical studies of statin therapy vs control (no statins) enrolling patients with small (<55 mm)
AAA,MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched. For each study, data
regarding AAA expansion in both the statin and control groups were used to generate standardized mean differences
(SMDs; <0 favoring statin therapy; >0 favoring control) and 95% confidence intervals (CIs). Study-specific estimates
were combined using inverse variance-weighted averages of logarithmic SMDs in fixed-effects and random-effects
models.
Results: We identified five clinical controlled studies of statin therapy vs control enrolling patients with small AAA,
including no randomized and five observational studies. Our meta-analysis included data on 697 patients with small AAA
received statin therapy or no statins. Pooled analysis demonstrated that statin therapy was statistically significantly
associated with less expansion rates (random-effects SMD, 0.50; 95% CI, 0.75 to 0.25; P  .0001). There was
statistically significant trial heterogeneity of results (P  .03). Exclusion of any single trial from the analysis did not
substantively alter the overall result of our analysis. There was no evidence of significant publication bias (P  .81).
Conclusion: Statin therapy is associated with less expansion rates in patients with small AAA. To confirm our results and
more accurately assess the effect of statins on AAA expansion, a large randomized trial is needed. (J Vasc Surg 2010;52:
1675-81.)Although several studies have found an association
between the presence of abdominal aortic aneurysm (AAA)
and the concentration of total cholesterol,1,2 there is no
clear relationship between total cholesterol and AAA ex-
pansion.3,4 Despite the absence of a relationship between
cholesterol and AAA expansion, there is evidence from a
number of studies to suggest that statin therapy may be
associated with less AAA expansion, presumably through its
pleiotropic effects.5 A meta-analysis by Guessous et al6 of
two cohort studies7,8 found statin therapy appeared to hold
promise for being associated with less AAA expansion. Our
preliminary meta-analysis9 of three observational clinical
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doi:10.1016/j.jvs.2010.04.082studies8,10,11 also suggested that statin therapy was associ-
ated with less AAA expansion. Since these meta-analyses6,9
were conducted, however, a number of clinical studies have
provided the association of statin therapy on less AAA
expansion. To confirm whether statin therapy is associated
with less AAA expansion, we performed an updated meta-
analysis of clinical controlled studies of statin therapy for
prevention of AAA expansion.
METHODS
Search strategy. All clinical studies of statin therapy vs
control (no statins) that enrolled patientswith small AAAwere
identified using a two-level search strategy. First, public do-
main databases, including MEDLINE, EMBASE, and the
Cochrane Central Register of Controlled Trials, were
searched usingWeb-based search engines (PubMed, OVID).
Second, relevant studies were identified through a manual
search of secondary sources, including references of initially
identified articles and a search of reviews and commentar-
ies. All references were downloaded for consolidation,
elimination of duplicates, and further analysis.
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1966 to December 2009. MeSH keywords included aortic
aneurysm, abdomen, and hydroxymethylglutaryl-CoA reduc-
tase inhibitors. Exploding keywords included abdominal
aortic aneurysm, hydroxymethylglutaryl-CoA reductase in-
hibitors, and statin. The Cochrane Library and Central
Register of Controlled Trials (current through December
2009) and the EMBASE database (January 1991 to Decem-
ber 2009) were searched using the OVID exploding key-
words abdominal aortic aneurysm, hydroxymethylglutaryl-
CoA reductase inhibitors, and statin.
Study selection and data abstraction. Studies con-
sidered for inclusion met the following criteria: the design
was a clinical controlled study, the study population com-
prised patients with small (55-mm) AAA, patients re-
ceived statin therapy vs no statins (control), and main
outcomes included AAA expansion. We included not only
studies providing expansion rates adjusted for potentially
confounding variables but also studies reporting unad-
justed expansion rates. A Quality of Reporting of Meta-
analyses (QUOROM)12 flow diagram of the study selec-
tion process is illustrated in Fig 1. Data regarding detailed
inclusion criteria, statin type, duration of follow-up, and
AAA expansion were abstracted (as available) from each
individual study. According to the guidance to authors for
the preparation of Cochrane Intervention reviews,13 we
imputed missing data (means and standard deviations
[SDs]) of expansion rates.
Statistical analysis. For each study, AAA expansion
data in the statin and control groups were used to generate
standardized mean differences (SMDs; 0 favors statin
therapy; 0 favors control) and 95% confidence intervals
(CIs). Study-specific estimates were combined using in-
Fig 1. A Quality of Reporting of Meta-analyses (QUROM)12
flow diagram for the meta-analysis.verse variance-weighted averages of logarithmic SMDs inboth fixed-effects and random-effects models. Between-
study heterogeneity was analyzed by means of standard 2
tests. Where no significant statistical heterogeneity was
identified, the fixed-effects estimate was used preferentially
as the summary measure. Sensitivity analyses were per-
formed to assess the contribution of each study to the
pooled estimate by excluding individual studies one at a
time and recalculating the pooled SMD estimates for the
remaining studies (leave-one-out meta-analysis). To assess
the effect of qualitative heterogeneity in study design on
the pooled effect estimate, the effects of statin therapy on
AAA expansion were explored separately in studies provid-
ing adjusted and unadjusted expansion rates. Publication
bias was assessed graphically using a funnel plot and math-
ematically using an adjusted rank correlation test.14 All
analyses were conducted using Review Manager 5.0,15
Comprehensive Meta-Analysis 2 (Biostat, Englewood,
NJ), and Meta-Analyst 3.0 software.16
RESULTS
As outlined in Fig 1, our search identified five clinical
controlled studies7,8,10,11,17 of statin therapy vs control that
enrolled patients with small AAA. These included no random-
ized and five observational studies. Our meta-analysis in-
cluded data on 697 patients with small AAA received statin
therapy or no statins. The baseline characteristics for the
patients enrolled in each study are summarized in the
Table.
Sukhija et al7 reported the size of AAAs at long-term
follow-up in 130 patients with AAAs who were not treated
surgically and in those treated with and without statins. At
long-term follow-up of patients treated with statins, serum
low-density lipoprotein cholesterol decreased from 142 
18 to 90  17 mg/dL (P  .001), serum high-density
lipoprotein cholesterol increased from 43  6 to 46  6
mg/dL (P .001), and serum triglycerides decreased from
137 19 to 120 20 mg/dL (P .001). AAA sizes were
measured by computed tomography (CT) scans at baseline
and at the last follow-up and were 46  6 mm at baseline
and 45 6 mm at the 23 7-month follow-up in patients
treated with statins (P  NS) and 45  6 mm at baseline
and 53 6 mm at the 24 7-month follow-up in patients
not treated with statins (P .001). Mortality at long-term
follow-up was 5% (45  8 months) in patients with AAAs
treated with statins and 16% (44  8 months) in those
without statin treatment (P  .05).
A retrospective analysis by Schouten et al8 included 150
patients under surveillance with a follow-up (every 6 to 12
months by means of ultrasound imaging) for aneurysm
expansion of at least 12 months and a minimum of three
diameter evaluations. Multiple regression analysis (age,
gender, AAA diameter at initial presentation, nonsteroidal
anti-inflammatory drug use, statin use, and cardiovascular
risk factors were used as independent variables), weighted
with the number of observations (ie, number of ultrasound
measurements), was performed to test the influence of
statins on AAA expansion rate. Statin users had a mean
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Variables Karlsson 200917 Mosorin 200811 Schlösser 200810 Schouten 20068 Sukhija 20067
Primary outcomes Correlation between
plasma levels of
IL-6, MMP-9,
and CRP and
with AAA
expansion
Association of statins
with AAA
expansion and
aneurysm repair or
rupture
Rupture rates, risks
of mortality, and
predictors of
AAA expansion
Association of statins
with AAA
expansion
Association of statins
with mortality and
AAA expansion
Statin type NR NR NR Atorvastatin Atorvastatin
Fluvastatin Simvastatin
Pravastatin
Simvastatin
Patients, No.
Statins 85 34 63a 59 75
No statins 127 87 84 91 55
AAA diameter, mm
Statins NR 39  7 NR 40  9 46  6
No statins NR 39  6 NR 37  7 45  6
Total 40 (37-44)b . . . 39  7 . . . . . .
P NR .94 NR .02 NS
AAA surveillance US US US US CT
Follow-up
Statins NR NR NR 2.9 yc 23  7 mo
No statins NR NR NR 3.2 yc 24  7 mo
Total 18 mon 3.6  2.2 y 4.0  2.5 y . . . . . .
P NR NR NR .49 NS
Age, y
Statins NR 71  8 NR 69  8 67  8
No statins NR 70  8 NR 69  8 66  8
Total 71 (67-75)d . . . 65  8 . . . . . .
P NR .73 NR .94 NS
Female, %
Statins NR 12 NR 14 16
No statins NR 10 NR 18 18
Total 23 . . . 11 . . . . . .
P NR .76 NR .44 NS
CAD, %
Statins NR 76 NR 51 69
No statins NR 51 NR 48 64
Total 31 . . . 39 . . . . . .
P NR .01 NR NR NS
CVD, %
Statins NR 21 NR 14 NR
No statins NR 13 NR 12 NR
Total 14 . . . 14 . . . . . .
P NR .27 NR 1.00 NR
DM, %
Statins NR 15 NR 15 24
No statins NR 10 NR 11 22
Total 4 . . . 24 . . . . . .
P NR .53 NR .32 NS
Hypertension, %
Statins NR 44 NR 47 64
No statins NR 44 NR 40 62
Total 59 . . . 87 . . . . . .
P NR 1.00 NR .30 NS
COPD, %
Statins NR 21 NR 29 NR
No statins NR 37 NR 26 NR
Total 6 . . . . . . . . . . . .
P NR .13 NR .85 NR
PAD, %
Statins NR 9 NR 29 NR
No statins NR 8 NR 10 NR
Total . . . . . . 16 . . . . . .
P NR 1.00 NR .01 NR
rror.
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sion rate compared with nonusers.
In an observational cohort study by Schlösser et al,10
AAA ultrasound measurements (every 12 months for AAAs
with a diameter between 30 and 39mm and every 6months
for AAAs with a diameter of 40 to 55 mm) were performed
for a period of6months in 147 of 230 patients with a 30-
to 55-mm AAA. Multivariable regression analysis was per-
formed to calculate the effects of demographic patient
characteristics, initial AAA diameter, and cardiovascular risk
factors on AAA growth. Patients using lipid-lowering drugs
(2% of the patients used nonstatins) had a mean 1.2-mm/y
(95% CI, 2.34-0.060 mm/y) lower AAA expansion rate
than nonusers of these drugs. After adjustments for age, no
significant association between lipid-lowering drug use and
survival time was found (P  .30).
The retrospective study by Mosorin et al11 included
121 patients with a 30-mm AAA undergoing ultrasound
surveillance (at 3- to 12-month intervals according to AAA
Fig 2. Forrest plot shows the standardized mean diff
Confidence interval; IV, inverse variance; SE, standard e
Table. Continued
Variables Karlsson 200917 Mosorin 200811
Smoking, %
Statins NR 62
No statins NR 87
Total 38 . . .
P NR NR
Medication
-blocker, % . . . . . .
Statins NR 71
No statins NR 49
Total
P NR .43
ACE inhibitor, %
Statins NR 15
No statins NR 10
Total 30 . . .
P NR .53
AAA, Abdominal aortic aneurysm;ACE, angiotensin converting enzyme;C
C-reactive protein;CT, computed tomography;CVD, cerebrovascular diseas
NR, not reported; NS, not significant; PAD, peripheral artery disease; US,
a2% of the patients used nonstatin drugs.
bMedian and range.
cMedian.
dMedian and interquartile range.diameter and patients’ conditions) for at least 1 year. Themean aneurysm expansion rate did not differ between
patients treated and not treated with statins (1.9  1.8
mm/y vs 2.6 2.4mm/y, P .27). In a study by Karlsson
et al,17 213 patients with a 35 to 49-mm AAA were
followed-up with ultrasound examination every 6 months
for a minimum of 18 months. Patients receiving statin
medication had a lower median expansion rate than pa-
tients not taking statins of 1.6 vs 2.5 mm/y (95% CI for the
difference, 0.03-1.5 mm/y; P  .008).
Although Sukhija et al7 and Mosorin et al11 provided
bothmeans and SDs of expansion rates, Schouten et al8 and
Schlösser et al10 reported means and 95% CIs instead of
SDs, and Karlsson et al17 provided a median instead of a
mean and a 95% CI instead of a SD. According to the
guidance to authors for the preparation of Cochrane Inter-
vention reviews,13 we imputed a missing mean in the study
by Karlsson et al17 and missing SDs in the studies by
Schouten et al,8 Schlösser et al,10 and Karlsson et al.17
Pooled analysis demonstrated statistically significantly
e of abdominal aortic aneurysm expansion rates. CI,
Schlösser 200810 Schouten 20068 Sukhija 20067
R 68 28
R 73 25
40 40 . . .
R .72 NS
. . . . . . . . .
R 41 77
R 32 67
R .28 NS
R 20 75
R 29 71
. . . . . . . . .
R .24 NS
ronary artery disease;COPD, chronic obstructive pulmonary disease;CRP,
, diabetes mellitus; IL-6, interleukin-6;MMP-9,matrix metalloproteinase-9;
und imaging.erencN
N
N
N
N
N
N
N
N
AD, co
e;DM
ultrasolower expansion rates with statin therapy (random-effects
ne-ou
ion b
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There was statistically significant trial heterogeneity of re-
sults (P .03). When data from studies providing adjusted
and unadjusted expansion rates were separately pooled,
statin therapy was associated with lower expansion rates
that remained statistically significant for adjusted studies
(fixed-effects SMD,0.40; 95% CI,0.63 to0.17; P
.0006; P for heterogeneity  .87) and for unadjusted
studies (random-effects SMD, 0.58; 95% CI, 1.04 to
Fig 3. Leave-o
Fig 4. Funnel plot shows the precis0.12; P  .01; P for heterogeneity  .008). Exclusion ofany single trial from the analysis (leave-one-outmeta-analysis)
did not substantively alter the overall result of our analysis
(Fig 3).
To assess publication bias, we generated a funnel plot of
the effect size vs the reciprocal of the standard error for each
study (Fig 4). Although the adjusted rank correlation test14
did not indicate publication bias (P  .81), there is clearly
limited power to detect such bias and accordingly it is difficult
to assess, given the small number of only five studies exam-
t meta-analysis.
y the standardized mean difference.ined.
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Our analysis showed that statin therapy was associated
with lower expansion rates in patients with small AAA,
which suggests that statins may reduce AAA expansion.
Despite the absence of a clear relationship between serum
cholesterol level and AAA expansion, statin therapy is ex-
pected to prevent AAA development because the pleiotro-
pic effects of statins include an anti-inflammatory effect,
antioxidative effect, and the reduction of matrix metallo-
proteinase (MMP) secretion.18 Statins reduce the tissue
levels of MMP-9 in human AAA specimens explanted for
culture.
Nagashima et al19 suggested that cerivastatin could
directly modulate the biology of the AAA wall and sup-
pressed MMP-9 production in the AAA wall by inhibiting
the activation of neutrophils and macrophages. Evans et
al20 demonstrated a reduction in MMP-9 levels in the AAA
wall in patients randomized to simvastatin. Furthermore,
Wilson et al21 showed that simvastatin, pravastatin, and
atorvastatin decreased concentrations of MMP-3 and
MMP-9 in the anterior AAA wall of humans undergoing
asymptomatic repair. In experimental studies, simvastatin
suppressed AAA progression in a mouse model, accompa-
nied by a reduction of MMP-9 and an increase of tissue
inhibitors of metalloproteinase-1, whereas inflammatory
cell infiltration was not inhibited.22,23
Shiraya et al24 demonstrated an inhibitory effect of
atorvastatin in an elastase-induced rat AAA model. How-
ever, atorvastatin suppressed macrophage recruitment into
the vascular wall through the inhibition of intercellular adhe-
sion molecule-1 and monocyte chemoattractant protein-1
expression, leading to the inhibition of MMP-12, but not
MMP-9 expression. Therefore, it is suggested that the
suppression of AAA development by atorvastatin was
mainly dependent on its anti-inflammatory effect.18
Karlsson et al25 demonstrated that patients taking ace-
tylsalicylic acid (ASA) had lower expansion rates than those
not taking ASA (0.18 vs 0.26 cm/y, P  .004) and that
patients taking statins and ASA together had a significantly
reduced expansion rate than patients who did not take
statins or ASA (0.14 vs 0.27 cm/y, P  .001). Statins and
ASA have different anti-inflammatory properties, which
might explain the complementary effect, although ASA
seems to bemore effective than statins (0.19 vs 0.23 cm/y).
Meanwhile, an association of oxidative stress with the
formation of AAA has been suggested. Reactive oxygen and
nitrogen species are increased in the human aneurysmal
wall compared with the normal aorta and adjacent nonan-
eurysmal aortic wall.26 Overexpressed reactive oxygen spe-
cies and nitric oxide increased the expression of MMPs
through the activation of nuclear factor B and induced
apoptosis of vascular smooth muscle cells in the aneurysm
wall.27-29 Statins may improve endothelial function through
their antioxidant effects.
The results of the present meta-analysis are consistent
with and strengthen those of previous meta-analyses.6,9Pooled results of two cohort studies7,8 in the meta-analysisby Guessous et al,6 representing 280 patients, showed a
significant decrease of expansion rate, with a fixed-effects
mean difference (MD) of2.97 mm/y (95% CI,5.83 to
0.11 mm/y). Pooled analysis of three observational clin-
ical studies8,10,11 in our preliminary meta-analysis,9 repre-
senting 418 patients, also demonstrated a significant reduc-
tion in expansion rate with statin therapy relative to control,
with a random-effects MD of 1.00 mm/y (95% CI,
1.54 to 0.47 mm/y; P  .0002).
In the present meta-analysis, we combined five studies,
representing 697 patients, and the pooled result was robust
in sensitivity analyses. Although the SMDs of AAA expan-
sion rates were similar (0.41 to0.31) in four8,10,11,17 of
the five studies included in the present meta-analysis, only
the study by Sukhija et al7 provided 1.06 of the SMD.
The mean or median diameters of the baseline AAA were
40 mm in the four studies,8,10,11,17 but in the study by
Sukhija et al,7 the mean diameter was 46 mm in the statin
group and 45 mm in the control group. These findings
suggest that the inhibitory effect of statin therapy for AAA
expansion may depend on the diameter of AAA.
Our analysis, however, must be viewed in the context of
its limitations. The major limitation of our study is that we
combined only observational studies, and therefore, the
treatment strategy was not based on randomized assign-
ment. Our findings are subject to selection bias and con-
founding. To minimize these biases, Schouten et al8 and
Schlösser et al10 used a multivariate linear regression model
and provided not unadjusted but adjusted effect estimates.
Nevertheless, hidden bias may remain because of the influ-
ence of unmeasured confounders. The other three stud-
ies7,11,17 provided only unadjusted effect estimates. In
nonrandomized observational studies, it is always necessary
to adjust for confounding, otherwise the results are subject
to some degree of bias. To confirm our results and more
accurately assess the effect of statins on AAA expansion, a
large randomized trial is needed. Because most patients
with AAA may have indications for statin therapy, they are
evaluated for these indications and statin therapy should be
started if such indications are present. In the absence of any
indications for statin therapy, the use of statins could be
considered based on what appears to be amodest inhibitory
effect on aneurysm expansion.
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